Angiotensin converting enzyme inhibitors in nondiabetic renal disease

Abstract

The class of antihypertensive agents that act by blocking angiotensin II has been shown in several experimental models to have the interesting ability to protect the kidney. In patients with nondiabetic renal disease, a number of controlled clinical trials have shown angiotensin converting enzyme inhibitors to achieve a better control of blood pressure and significantly reduce the rate of progression of renal failure in comparison with conventional agents. In addition, treatment with angiotensin converting enzyme inhibitors has helped to achieve new information on the optimal blood pressure target to be reached in order to protect the residual renal function maximally.